Low-level viremia in people with HIV in Ethiopia is associated with subsequent lack of viral suppression and attrition from care
Open Access
- 13 February 2025
- journal article
- Published by Taylor & Francis in Global Health Action
- Vol. 18 (1) , 2464342
Abstract
Low-level viremia during antiretroviral therapy (ART) has been associated with inferior outcomes, but knowledge on the impact of low-level viremia in the current era of dolutegravir-based ART in low-income countries is limited. To investigate whether low-level viremia predicts virologic non-suppression and attrition from care in people with HIV receiving ART in Ethiopia. We included people receiving ART at public health facilities in an urban area in central Ethiopia and categorized persons with ≥1 available viral load 2019–2020 as having either suppression (1,000 copies/mL were excluded. We used multivariable logistic regression adjusted for age, sex, ART regimen, type of health facility, and duration of ART to analyze the associations between viremia category and incidence of unsuppressed viral load (>1,000 copies/mL) and attrition from care (death or loss to follow-up) during 3 years of follow-up. Among 12,165 participants, the median age was 44 years, 64.2% were female, and 89.1% received tenofovir/lamivudine/dolutegravir. Of the study population, 11,959 (98.3%) had suppression and 206 (1.7%) had low-level viremia. Over 3 years of follow-up, 2.2% of participants with suppression and 11.3% with low-level viremia had unsuppressed viral load. Low-level viremia was associated with both unsuppressed viremia (adjusted odds ratio [aOR], 3.7; 95% confidence interval [CI], 2.2–6.2) and attrition (aOR, 3.4; 95% CI, 1.7–6.6). Among Ethiopian people with HIV receiving ART, low-level viremia predicted subsequent virologic non-suppression and attrition from care, supporting current recommendations for heightened attention to low-level viremia in ART recipients.Keywords
Funding Information
- Development, Region Kronoberg
This publication has 24 references indexed in Scilit:
- Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: An open-label randomized controlled trial in LesothoPLOS Medicine, 2020
- All-Cause Mortality and Serious Non-AIDS Events in Adults With Low-level Human Immunodeficiency Virus Viremia During Combination Antiretroviral Therapy: Results From a Swedish Nationwide Observational StudyClinical Infectious Diseases, 2020
- How relevant is the HIV low level viremia and how is its management changing in the era of modern ART? A large cohort analysisJournal of Clinical Virology, 2020
- Outcomes and factors affecting mortality and successful tracing among patients lost to follow-up from antiretroviral therapy in Pawi Hospital, Northwest EthiopiaTropical Medicine and Health, 2019
- Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort studyThe Lancet Infectious Diseases, 2018
- Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatmentPLOS ONE, 2017
- Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patientsAIDS, 2015
- Rate of and Predicting Factors for Virologic Failure in HIV-Infected Patients with Persistent Low-Level Viremia under Antiretroviral TherapyJournal of the International Association of Providers of AIDS Care (JIAPAC), 2014
- Comparative Performances of HIV-1 RNA Load Assays at Low Viral Load Levels: Results of an International CollaborationJournal of Clinical Microbiology, 2014
- Evidence that Low-Level Viremias during Effective Highly Active Antiretroviral Therapy Result from Two Processes: Expression of Archival Virus and Replication of VirusJournal of Virology, 2005